Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H13NO2 |
| Molecular Weight | 155.1943 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(C)CC(=O)NC(=O)C1
InChI
InChIKey=ORRZGUBHBVWWOP-UHFFFAOYSA-N
InChI=1S/C8H13NO2/c1-3-8(2)4-6(10)9-7(11)5-8/h3-5H2,1-2H3,(H,9,10,11)
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/mesh/68001534 and http://www.ncbi.nlm.nih.gov/pubmed/13489272
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/mesh/68001534 and http://www.ncbi.nlm.nih.gov/pubmed/13489272
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. Bemegride is an antidote for barbiturate poisoning. Bemegride has being shown to have an antagonistic action on the GABAA receptor.
CNS Activity
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
14 g 1 times / 4 min multiple, intravenous (total) Highest studied dose Dose: 14 g, 1 times / 4 min Route: intravenous Route: multiple Dose: 14 g, 1 times / 4 min Co-administed with:: amiphenazole, i.v(4.2 g, total for 4 days) Sources: Page: p.758 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Barbiturate poisoning Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.758 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Anti-convulsant effect of phthalazino-2,3b-phthalazine-5(14H),12(7h)-dione (L-5418). I. Behavioral effect. | 1978 Feb |
|
| Decreased convulsant potency of picrotoxin and pentetrazol and enhanced [3H]flunitrazepam cortical binding following stressful manipulations in rats. | 1980 May 12 |
|
| [Behavioral pharmacology of mianserin hydrochloride, a new antidepressant (author's transl)]. | 1980 Sep |
|
| Pharmacological studies on a new dihydrothienopyridine calcium antagonist, S-312-d. 5th communication: anticonvulsant effects in mice. | 1994 Jun |
|
| [Changes in energy metabolism in the brain of bemegride-kindled rabbits]. | 2002 |
|
| Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. | 2006 Apr 24 |
|
| Changes of serum adrenocorticotropic hormone and cortisol levels during sleep seizures. | 2008 Apr |
|
| Bemegride lengthens seizure duration during electric convulsive therapy in a schizophrenic patient with increased seizure threshold. | 2009 Mar |
|
| Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. | 2009 May |
Patents
Sample Use Guides
For the treatment of barbiturate poisoning - 10 ml (50 mg) of bemegride, being injected every three to five minutes
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
R07AB05
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
||
|
WHO-VATC |
QR07AB05
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID0045250
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
C76617
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
200-588-0
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
2310
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
SUB05691MIG
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
58187
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
3013
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
100000086119
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
64-65-3
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
511
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
57DQA39DO2
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
m2299
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
D001534
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
Bemegride
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1214192
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY | |||
|
DB13740
Created by
admin on Fri Dec 15 15:06:14 GMT 2023 , Edited by admin on Fri Dec 15 15:06:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
